Ledermann, Jonathan

ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma

Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer

Endometrial and Cervical Cancer TreatmentsOvarian cancer diagnosis and treatment

Cited by 1,989

Homologous recombination deficiency and ovarian cancer

Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 258

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions

Karam, A., Ledermann, J. A., Kim, J.-W., Sehouli, J., Lu, K., Gourley, C., Katsumata, N., Burger, R. A., Nam, B.-H., Bacon, M., et al. (2017) · Annals of Oncology

Ovarian cancer diagnosis and treatmentEndometrial and Cervical Cancer Treatments

Cited by 153

Molecular and Clinical Predictors of Improvement in Progression‐free Survival with Maintenance PARP Inhibitor Therapy in Women with Platinum‐sensitive, Recurrent Ovarian Cancer: A Meta‐analysis

Lee, C. K., Friedlander, M. L., Tjokrowidjaja, A., Ledermann, J. A., Coleman, R. L., Mirza, M. R., Matulonis, U. A., Pujade‐Lauraine, E., Bloomfield, R., Goble, S., et al. (2021) · Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 36

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol

Gillessen, S., Murphy, L., James, N. D., Sachdeva, A., El-Taji, O., Abdel-Aty, H., Adler, A. I., Amos, C., Attard, G., Varughese, M., et al. (2025) · The Lancet Oncology

Metabolism, Diabetes, and CancerProstate Cancer Treatment and Research

Cited by 28